Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-06-04
2000-03-21
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
06040292&
ABSTRACT:
The invention provides new methods for the treatment of diabetes mellitus, including type I, type II, and insulin resistant diabetes (both type I and type II). The methods of the invention employ administration of rhIGF-I/IGFBP-3 complex to a subject suffering from the symptoms of diabetes mellitus. Administration of rhIGF-I/IGFBP-3 to a subject suffering from the symptoms of diabetes mellitus results in amelioration or stabilization of the symptoms of diabetes.
REFERENCES:
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5674845 (1997-10-01), MacCuish
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5686408 (1997-11-01), Moses et al.
patent: 5723441 (1998-09-01), Higley et al.
Blum et al., 1991, "Plasma IGFBP-3 Levels as Clinical Indicators "in Modern Concepts in Insulin-Like Growth Factors, E.M. Spencer, ed., Elsevier, New York, pp. 381-393.
Clark et al., 1993, "Insulin-like Growth Factor-I Stimulation of Lymphopoiesus "J. Clin. Invest.92:540-548.
Clemmons et al., 1994, "Uses of Human Insulin-like Growth Factor-1 in Clinical Conditions "J. Clin. Endocrinol. Metabol.79(1):4-6.
Delany et al., 1994, "Cellular and Clinical Perspectives on Skeletal Insulin-like Growth Factor I "J. Cell. Biochem. 55:328-333.
Guler et aL., 1987, "Short-term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy Adults", New England J. Med. 317(3):137-140.
Lewis et al., 1993, "Insulin-like Growth Factor I: Potential for Treatment of Motor Neuronal Disorders "Exp. Neurol. 124:73-88.
Lieberman et al., 1992, "Effects of Recombinant Human Insulin-like Growth Factor-I (rhIGF-I) on Total and Free IGF-I Concentrations, IGF-Binding Proteins, and Glycemic Response in Humans", J. Clin. Endocrinol. Metab. 75(1):30-36.
Radulescu, Razvan T., 1994, Trends Biochem Sci. 19(7):278.
Sommer et al., 1991, "Molecular Genetics and Actions of Recombinant Insulin-Like Growth Factor Binding Protein-3", in Modem Concepts of Insulin-Like Growth Factors, E.M. Spencer, ed., Elsevier, New York, pp. 715-728.
Steenfos, Henrik H., 1994, "Growth Factors and Wound Healing "Scand. J. Plast. Reconstr. Hand Surg. 28:95-105.
Zapf et al., 1994, "Intravenously Injected Insulin-like Growth Factor (IGF) I/IGF Binding Protein-3 Complex Exerts Insulin-like Effects in Hypophysectomized, but Not in Normal Rats", J. Clin. Invest. 95:179-186.
Celtrix Pharmaceuticals Inc.
Henley III Raymond
LandOfFree
Methods for treating diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730436